NAD+ · Research brief
Peptides for Chronic Fatigue: Research Buyer's Guide
Short answer
The compounds that dominate the fatigue literature are rarely the ones marketed hardest. MOTS-c, a 16-amino-acid peptide encoded inside mitochondrial DNA rather than nuclear DNA, has generated more serious bioenergetics research than most of the recovery compounds promoted alongside it. Our team fields procurement questions about peptides for chronic fatigue research nearly every week, and the pattern is consistent.
Key takeaways
- There is no single compound among the peptides for chronic fatigue research category; the literature splits across bioenergetic, neuroendocrine, inflammatory, and behavioral mechanisms that require different endpoints.
- MOTS-c is encoded within the mitochondrial 12S rRNA region and was first described in Cell Metabolism in 2015, making it the only widely available compound whose gene sits inside the mitochondrion.
- 5-Amino-1MQ and NAD+ are not peptides; they are an NNMT inhibitor and a dinucleotide coenzyme, and mislabeling them in a methods section is a common error.
- Net peptide content is lower than gross vial weight because of counterion and residual moisture, so concentration calculations built on gross mass carry systematic error.
- Lot-specific certificates showing an HPLC chromatogram plus mass spectrometry identity are the minimum acceptable documentation, and Real Peptides publishes them for catalog compounds.
- Lyophilized material is generally stored at -20C and reconstituted solution at 2C to 8C, with repeated freeze-thaw cycling treated as a degradation risk.
The compounds that dominate the fatigue literature are rarely the ones marketed hardest. MOTS-c, a 16-amino-acid peptide encoded inside mitochondrial DNA rather than nuclear DNA, has generated more serious bioenergetics research than most of the recovery compounds promoted alongside it.
Our team fields procurement questions about peptides for chronic fatigue research nearly every week, and the pattern is consistent. The compound gets chosen before the endpoint does. That order needs reversing, and this page is built to reverse it.
Which peptides for chronic fatigue does the research literature actually focus on?
Work on peptides for chronic fatigue clusters around three groups: mitochondrial-derived peptides such as MOTS-c, NAD+ pathway compounds including the NNMT inhibitor 5-Amino-1MQ, and neuroendocrine secretagogues like CJC-1295 no DAC and Ipamorelin. All are research use only. Selection should follow the measurable endpoint, never the marketing category.
There is no single fatigue peptide, and any supplier implying one exists is selling a narrative rather than a research tool. Fatigue in a research model is a downstream readout of at least three separable systems: cellular energy production, neuroendocrine rhythm, and inflammatory signaling. What follows covers which compounds map to which mechanism, how those mechanisms compare head to head, and how to verify identity and purity before a purchase order leaves the lab.
Where fatigue research starts: three mechanistic targets
Most published investigation into peptides for chronic fatigue sorts into three mechanistic buckets, and a compound that fits one bucket will produce nothing useful in a study designed around another.
Bioenergetics. This is the mitochondrial bucket: oxidative phosphorylation efficiency, electron transport chain function, cardiolipin integrity in the inner mitochondrial membrane, and AMPK (AMP-activated protein kinase) signaling, the enzyme switch that shifts cells from storage toward substrate oxidation. MOTS-c, 5-Amino-1MQ, and NAD+ sit here.
Neuroendocrine rhythm. Growth hormone release is pulsatile and tightly coupled to slow-wave sleep. GHRH analogs such as Sermorelin, Tesamorelin, and CJC-1295 no DAC, along with the GHS-R1a receptor agonist Ipamorelin, are studied for their effect on GH pulsatility, IGF-1, and sleep architecture rather than on cellular energy directly.
Inflammatory and redox signaling. KPV, the C-terminal tripeptide of alpha-MSH, and the 15-amino-acid gastric peptide BPC-157 appear in mucosal and gut-brain axis work, while glutathione, a tripeptide of glutamate, cysteine and glycine, functions as the primary intracellular redox buffer.
A fourth, smaller line of work sits on behavioral readouts: Selank, a synthetic heptapeptide analog of the immunopeptide tuftsin, has been studied in rodent anxiety and asthenia models. In our experience, labs that pick a bucket first and a compound second design cleaner studies.
Why mitochondrial-derived peptides dominate the energy-metabolism literature
MOTS-c is the most-studied compound in the peptides for chronic fatigue conversation because it is the only one whose gene sits inside the mitochondrion itself. It is translated from a short open reading frame within the mitochondrial 12S rRNA region and was first described in Cell Metabolism in 2015 by a research group at the University of Southern California. Studies report that under metabolic stress MOTS-c translocates to the nucleus and influences nuclear gene expression, with AMPK activation and folate-methionine cycle interference described as central mechanisms. Research also reports exercise-induced increases in skeletal muscle MOTS-c, which is why exercise-capacity models keep recurring in the literature.
The NAD+ angle runs parallel. Intracellular NAD+ is the redox cofactor that oxidative phosphorylation and the sirtuin enzymes depend on, and it declines with age. 5-Amino-1MQ is not a peptide at all. It is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), the enzyme that methylates nicotinamide and removes it from the salvage pathway; inhibiting it is reported to spare nicotinamide and raise intracellular NAD+ in adipocyte models. Separately, the cardiolipin-binding peptide SS-31 (elamipretide) has been investigated in primary mitochondrial myopathy trials.
Here is the design error we see most often, and it has nothing to do with compound choice: researchers run a mitochondrial-mechanism peptide in a model with intact mitochondrial function, then report a null result. If baseline respiration is normal, a compound that restores impaired respiration has nothing to restore. Characterise the deficit before you order the compound.
How to vet a supplier before the purchase order goes out
Identity verification comes before purity, always. Before procurement, confirm three things on the lot-specific certificate of analysis: the CAS number, the full amino-acid sequence, and the measured molecular weight against the theoretical value. A compound sold under the right name with the wrong mass is not the compound.
Then read the purity documentation properly. A certificate should show an HPLC chromatogram with the retention time and integration visible, plus a mass spectrometry trace confirming molecular identity. A PDF that states a percentage with no underlying chromatogram is a marketing asset, not analytical data. Real Peptides posts publicly verifiable, lot-specific COAs for catalog compounds supplied for laboratory research.
One detail almost nobody checks: net peptide content versus gross vial weight. Synthetic peptides purified by reverse-phase HPLC typically carry a trifluoroacetate counterion plus residual moisture, and both add mass. The powder in the vial is heavier than the peptide in the vial. If a study's calculations are built on gross weight, every concentration in the protocol drifts, and the drift is systematic rather than random.
Handling matters just as much as sourcing. Lyophilized material is normally held at -20C, while reconstituted solution is refrigerated at 2C to 8C, and repeated freeze-thaw cycling is a known degradation pathway for peptides in solution. Small-batch synthesis with exact amino-acid sequencing exists precisely so that batch-to-batch variance does not become an uncontrolled variable in your data. Everything described here is laboratory research context: these compounds are research use only, are not approved drugs, and are not supplied for human or veterinary use.
Peptides for Chronic Fatigue: Mechanism-by-Mechanism Comparison
This table maps each commonly requested compound to the pathway it is actually studied in, so selection follows the endpoint. Compounds are grouped by mechanism, not by popularity.
| Compound | Structure | Pathway described in the literature | Typical research model | Bottom line for lab selection |
|---|---|---|---|---|
| MOTS-c | 16-amino-acid mitochondrial-derived peptide from the 12S rRNA region of mtDNA | AMPK activation, folate-methionine cycle, retrograde nuclear signaling under metabolic stress | Rodent metabolic and exercise-capacity work, skeletal muscle cell culture | The most direct bioenergetic probe available; strongest fit where respiration or substrate oxidation is the endpoint |
| 5-Amino-1MQ | Small molecule, not a peptide | NNMT inhibition sparing nicotinamide for NAD+ salvage | Adipocyte culture and diet-induced obesity models | Only worth including if the protocol has an NAD+ or methylation assay attached |
| NAD+ | Dinucleotide coenzyme, not a peptide | Redox cofactor for oxidative phosphorylation, substrate for sirtuins and PARPs | Aging and mitochondrial-decline models | Better as a comparator arm than a primary variable; delivery is the main design constraint |
| CJC-1295 no DAC | 29-amino-acid GHRH analog | GH pulsatility and downstream IGF-1 | Rodent GH-axis and sleep architecture studies | Neuroendocrine endpoints only; it will not move cellular energy markers directly |
| Ipamorelin | Pentapeptide GHS-R1a agonist | Selective GH release without strong ACTH or prolactin effect reported | Same GH-axis models, often paired with a GHRH analog | Chosen for selectivity when confounding pituitary output must be minimised |
| Selank | Synthetic heptapeptide, tuftsin analog | Monoamine and GABAergic modulation, BDNF expression reported in rodent work | Rodent anxiety and asthenia models | Behavioral fatigue readouts, not metabolic ones |
| KPV and BPC-157 | Tripeptide fragment of alpha-MSH; 15-amino-acid gastric peptide | NF-kB driven inflammatory signaling, mucosal integrity, gut-brain axis | Colitis and mucosal injury rodent models | Relevant only where the working hypothesis is inflammatory or gut-derived |
| Glutathione | Tripeptide: glutamate, cysteine, glycine | Primary intracellular redox buffer, ROS handling | Oxidative stress assays | Most useful as a redox control measure rather than a standalone variable |
What If: Research Procurement Scenarios
What if my model shows no mitochondrial deficit at baseline?
Change the model or change the compound. A peptide studied for restoring impaired respiration has no measurable target in tissue with normal oxygen consumption rate and normal spare respiratory capacity, which is the single most common reason bioenergetic study arms return null results. Either move to a model with a characterised deficit, or shift the hypothesis toward the neuroendocrine or inflammatory bucket where the readout is behavioral or cytokine-based rather than respirometric.
What if the lyophilized vial arrives at ambient temperature?
Document the excursion, then check the certificate for the manufacturer's stated stability conditions for that specific compound. Lyophilized peptides are considerably more thermally tolerant than reconstituted solution, and short ambient transit is standard practice across the industry, which is why material ships dry rather than pre-mixed. Temperature excursions matter far more once a compound is in solution, where hydrolysis and oxidation proceed at measurable rates.
What if two suppliers list the same compound at very different prices?
Compare net peptide content, purification method, and whether the certificate is lot-specific before comparing price per vial. A large price gap usually reflects one of three things: gross-weight labeling, a generic COA reused across lots, or crude material that has not been through preparative HPLC purification. Our team has reviewed enough incoming third-party certificates to say the documentation gap is almost always visible in the chromatogram.
What if a colleague asks which of these is best for chronic fatigue syndrome?
The accurate answer is that none of them are approved therapies for myalgic encephalomyelitis or chronic fatigue syndrome, and none are supplied for human use. ME/CFS has no approved pharmacotherapy, and the National Academy of Medicine's 2015 report on the condition underscored how thin the mechanistic evidence base still is. Research compounds are tools for generating that evidence, not shortcuts past it.
The Unglamorous Truth About Fatigue Peptide Claims
Let's be direct about this: most of what circulates online about peptides for chronic fatigue is mechanism extrapolated far past the data. A compound activating AMPK in a rodent skeletal muscle model tells you something real about that pathway. It tells you nothing about a human with unexplained exhaustion. The published work on MOTS-c, NAD+ metabolism, and GH secretagogues is genuinely interesting preclinical science, and it is preclinical. Anyone collapsing that distance for you is either careless or selling something. Buy the compound for the experiment you designed, and let the results be whatever they are.
Lot-specific certificates for every catalog compound are posted in our COA library, the full research catalog is at the shop, handling and purity questions are addressed in the peptide FAQ, and facility and shipping details live on our location page.
The interest in peptides for chronic fatigue exists because fatigue is one of the last major clinical complaints with almost no mechanistic consensus behind it, and that vacuum pulls in both serious research and confident nonsense at the same rate. The compounds worth your budget are the ones with a pathway you can assay, a certificate you can read, and a deficit in your model that the mechanism could plausibly touch. Everything else is expensive optimism in a sterile vial.
Build a pack
Researching more than one compound?
Build a multi-vial pack and the discount applies automatically as you add vials.
Questions
RESEARCH USE ONLY · NOT EVALUATED BY THE FDA